PharmaResearch Products, the South Korean manufacturer of Rejuran (polynucleotide skin booster), has acquired a cosmetic group, signaling aggressive portfolio consolidation in the biostimulator and skin-rejuvenation space. The deal expands PharmaResearch's footprint beyond its flagship PN platform into adjacent aesthetic categories.
Business & M&A
Rejuran Maker PharmaResearch Acquires Cosmetic Group
South Korean injectable manufacturer expands portfolio through acquisition.
Rejuran acquisition signals PharmaResearch's push into adjacent aesthetic categories.
Rejuran has gained traction in Asia-Pacific and emerging European markets as a lower-cost alternative to PLLA and CaHA biostimulators, targeting the preventive and maintenance-treatment segment. The acquisition likely aims to cross-sell Rejuran into the acquired group's distribution network and clinical practice base, accelerating market penetration. For U.S. practices, Rejuran remains unapproved by the FDA, though off-label use and medical tourism continue to drive awareness among patients seeking alternatives to established biostimulators.
Source: original report ↗
Frequently asked questions
Is Rejuran approved by the FDA in the United States?
No, Rejuran is not FDA-approved for use in the U.S. However, some practices use it off-label, and patients also seek it through medical tourism, particularly in Asia-Pacific markets where it is established and approved.
What is Rejuran and how does it work as a skin treatment?
Rejuran is a polynucleotide (PN) skin booster manufactured by South Korean company PharmaResearch Products. It functions as a biostimulator that stimulates collagen production for skin rejuvenation and is positioned as a lower-cost alternative to PLLA and calcium hydroxyapatite (CaHA) biostimulators.
How much does Rejuran cost compared to other biostimulators?
Rejuran is marketed as a lower-cost alternative to established biostimulators like PLLA and CaHA, though specific pricing varies by market and provider. It targets the preventive and maintenance-treatment segment where cost-conscious patients seek value.
Why did PharmaResearch acquire a cosmetic group?
The acquisition allows PharmaResearch to expand beyond its flagship Rejuran platform into adjacent aesthetic categories and cross-sell Rejuran through the acquired group's existing distribution network and clinical practices, accelerating market penetration.
What markets is Rejuran currently available in?
Rejuran has gained significant traction in Asia-Pacific and emerging European markets. It remains unapproved in the U.S., though awareness is growing among patients interested in biostimulator alternatives through medical tourism.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.